Coland Pharmaceutical

Coland Pharmaceutical is a specialty pharmaceutical company primarily focused on the development, manufacturing, and distribution of therapeutic products within the Chinese market. The company maintains a diverse portfolio across several key therapeutic areas, including hepatology, respiratory medicine, and cardiovascular health. Coland is recognized for its dual business model, which combines the development of its own proprietary drugs, such as the Hepatitis B treatment clevudine, with the distribution of high-quality products from international partners like Pfizer and Eisai. Following its privatization and delisting from the Taiwan Stock Exchange in 2020, the company has continued to strengthen its commercial infrastructure and R&D capabilities to address unmet medical needs in China. Its strategic focus remains on leveraging its deep understanding of the Chinese regulatory and market landscape to bring innovative treatments to patients.